Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kaleido Biosciences, Inc. (KLDO)

0.0003   0 (50%) 01-27 10:29
Open: 0.0004 Pre. Close: 0.0002
High: 0.0004 Low: 0.0003
Volume: 757 Market Cap: 0(M)

Technical analysis

as of: 2023-01-27 4:45:51 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0     One year: 0.01
Support: Support1: 0    Support2: 0
Resistance: Resistance1: 0    Resistance2: 0
Pivot: 0
Moving Average: MA(5): 0     MA(20): 0
MA(100): 0     MA(250): 0.3
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 0.5     %D(3): 12.2
RSI: RSI(14): 34.8
52-week: High: 1.91  Low: 0
Average Vol(K): 3-Month: 13 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ KLDO ] has closed above bottom band by 15.8%. Bollinger Bands are 106% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0

Company Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Headline News

Tue, 24 Jan 2023
Johnson & Johnson Reports Q4 and Full-Year 2022 Results - Investing News Network

Wed, 18 Jan 2023
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference - Investing News Network

Thu, 15 Dec 2022
Ice Storm Brings Down Two Broadcast Towers In South Dakota. - Inside Radio

Mon, 11 Apr 2022
Kaleido Biosciences Investor Alert: Kaplan Fox Investigates ... - GlobeNewswire

Fri, 08 Apr 2022
KLDO stock crashes on plans to delist from Nasdaq (NASDAQ:KLDO) - Seeking Alpha

Mon, 31 Jan 2022
Kaleido Biosciences cuts staff, COPD program - Boston Business ... - The Business Journals

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  PNK
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 43 (M)
% Held by Insiders 4.245e+007 (%)
% Held by Institutions 0.7 (%)
Shares Short 2,160 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.516e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -7
Return on Assets (ttm) 927.7
Return on Equity (ttm) -100
Qtrly Rev. Growth 1.1e+006
Gross Profit (p.s.) 186.36
Sales Per Share -1055.59
EBITDA (p.s.) -1.21273e+008
Qtrly Earnings Growth -2.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -77 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 2.34e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.